NASDAQ:PEPG
PepGen Inc. Stock News
$14.56
+0.320 (+2.25%)
At Close: May 24, 2024
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
04:02pm, Tuesday, 14'th May 2024
– CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – N et
Best Momentum Stocks to Buy for April 25th
11:00am, Thursday, 25'th Apr 2024
TXO, PEPG and ERO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 25, 2024.
New Strong Buy Stocks for April 25th
07:56am, Thursday, 25'th Apr 2024
TAK, TXO, PEPG, ERO and RMNI have been added to the Zacks Rank #1 (Strong Buy) List on April 25, 2024.
PepGen to Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 13'th Mar 2024
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
07:00am, Wednesday, 13'th Mar 2024
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?
10:55am, Tuesday, 12'th Mar 2024
The mean of analysts' price targets for PepGen, Inc. (PEPG) points to a 48.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 11'th Mar 2024
PepGen, Inc. (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PepGen, Inc. (PEPG) Q4 2023 Earnings Call Transcript
05:10pm, Thursday, 07'th Mar 2024
PepGen, Inc. (NASDAQ:PEPG ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Emiko Bryant - Chief of Staff James McArthur - President and CEO Michelle Mellion - SVP and H
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
04:01pm, Wednesday, 06'th Mar 2024
- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mg/kg dose cohort in mid-2024
BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
08:00am, Tuesday, 20'th Feb 2024
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
11:20am, Sunday, 18'th Feb 2024
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
07:30am, Wednesday, 07'th Feb 2024
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th
PepGen soars on Sarepta Therapeutics' Duchenne drug phase 2 data
06:06am, Tuesday, 06'th Feb 2024
PepGen Inc. NASDAQ: PEPG is a clinical-stage biotech focused on developing therapies for rare neuromuscular and neurological genetic diseases like Duchenne muscular dystrophy (DMD). PepGen utilizes it
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
07:00am, Wednesday, 17'th Jan 2024
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th